SMS Pharma Q1FY27 Investor Presentation filed with exchanges

Mgmt Guided Margin ImprovementAnalyst Day Multiyear TargetsOrder Pipeline DisclosedInvestor Communications View source PDF Explain this filing

SMSPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-2.9%1-day move

₹374.50

prior close

₹375.75

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.8-1.7-2.1-2.0-2.9-2.9-4.5+1.2+0.4-0.1————

Up moveDown movePending

AI summary

SMS Pharma filed its Q1FY27 investor presentation. Revenue grew 6 percent YoY to Rs 207 crore; EBITDA at Rs 41 crore with 20 percent margin; PAT up 8 percent to Rs 20 crore; EPS Rs 2.23. Gross margin held above 45 percent. Completed 4 DMF and CEP filings, targeting 10 in FY27. Rs 280 crore capex on track for FY27 completion, with brownfield focus. Board approved Rs 50 crore loan into subsidiary SMS Peptides for peptide R&D. Targets 1.75x asset turnover in 2-3 years and 20 filings over 24 months.

Likely market impact

Steady margins and earnings growth; capex and R&D expansion back multi-year targets. Watch capex returns and peptide subsidiary progress.